We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Robert Gish

Robert G. Gish MD, FAASLD

Principal, Robert G. Gish Consultants LLC; Clinical Professor of Medicine & Staff Physician, Loma Linda University Liver Transplant Institute, Las Vegas, Nevada; Adjunct Professor of Medicine, University of Nevada, Reno, Nevada; Adjunct Professor of Medicine, University of Nevada, Las Vegas, Nevada; Adjunct Professor of Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, California; Medical Director, Hepatitis B Foundation, Doylestown, Pennsylvania

Dr. Gish was first in Pharmacy School at the University of Kansas and then obtained his medical degree from the University of Kansas Medical School in Kansas City, Kansas. He completed a 3-year internal medicine residency at the University of California, San Diego, and a 4-year gastroenterology and hepatology fellowship at the University of California, Los Angeles which included transplant medicine.

Dr. Gish is a fellow of the American Association for the Study of Liver Disease, the American Society of
Transplantation and American College of Physicians.

He has served on the editorial boards of American Journal of Gastroenterology, Hepatology, Journal of Hepatology, Digestive Diseases and Sciences, and Gastroenterology, among many others. He co-authored a public health policy for liver health in Vietnam focusing on HBV and is also assisting with the development of viral hepatitis health care policies in Georgia, Armenia, and the Philippines. He was a major early contributor to decipherment methods for the detection of hepatitis B and C virus and characterizing its epidemiology and clinical presentation in humans. He was involved in studies that led to the genotypic classification strategies and methods now in use worldwide. He has published more than 700 original articles, abstracts, and book chapters.

Robert G. Gish, MD, is currently an Adjunct Professor of Medicine at the University of Nevada Schools of Medicine in Las Vegas and in Reno. He serves as an Adjunct Professor of Pharmacy at Skaggs School of Pharmacy and Pharmaceutical Sciences at UCSD, a Clinical Professor of Medicine at Loma Linda University as well as a Staff Physician at Loma Linda University’s Liver Transplant Clinic in Las Vegas. In addition, he is also Medical Director of the Asia Pacific Health Foundation in San Diego, CA and of the Hepatitis B Foundation in Doylestown, Pennsylvania. Dr. Gish is currently seeing patients, both in-person and via telemedicine, at various clinics in San Diego, Folsom, Fresno, San Jose and Las Vegas/Reno.

Disclosures

Dr. Gish reports the following:

Over 80% of income from Pharma derived from Dr. Gish’s work and consultation activities is directed to research, education, public policy and/or donated to charitable organizations.

Pharmaceutical Company Relationships
Dr. Robert Gish: Financial Disclosures relative to the pharmaceutical industry that are as follows:

Robert Gish, MD, has had a financial interest/relationship or affiliation in the form of:

Grants/Research Support in last 2 years:
Gilead

Dr. Gish has performed as Consultant and/or Advisor to (in the last two years):
Abbott, AbbVie, Access Biologicals, Antios, Arrowhead, Bayer AG, Bristol-Myers Squibb Company, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Forty-Seven Inc, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTX, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Salix, Shionogi, Viking Therapeutics 

Current Activity with Scientific or Clinical Advisory Boards:
Abbott, AbbVie, Merck, Arrowhead, Bayer, Dova Pharmaceuticals, Eiger, Enyo, HepQuant, Intercept, Janssen

Current Clinical Trials Alliance:
Topography Health

Chair Clinical Advisory Board:
Prodigy

Advisory Consultant: Diagnostic Companies:
Biocollections, Fujifilm/Wako, Quest

Data Safety Monitoring Board:
Arrowhead

Consulting Confidentiality Agreements as of 2020:

Abbvie: 2017-current
Abbott: 2016-current
Access Biologicals: 2016-current
ADMA Biologics: 2017-current
AEC Partners: 2017-current
Aligos Therapeutics: 2020-current
Arena Pharmaceuticals Inc: 2018-current
Arrowhead: 2011-current
Arterys Inc: 2018 - current
Alexion: 2018-current
Altimmune: 2020-current
Antios Therapeutics: 2018-current
AprosTx: 2020-current
Bayer: 2019-current
Cirina: 2017-current
Consumer Health Products Assoc: 2019-current
DiaSorin Inc: 2020-current
Dova Pharmaceuticals: 2017-current
DRG Abacus: 2018-current
DURECT Corporation: 2020-current
Dynavax: 2018-current
Echosens: 2020-current
Eiger: 2015-current
Enyo: 2017-current
Exelixis: 2018-current
Forty-Seven Inc: 2019-current
Fujifilm Wako Diagnostics: 2019-current
Gilead: 2018-current
HepQuant: 2018-current
HepaTx: 2017-current
IDLogiq: 2020-current
Intellia: 2015-current
Intercept 2010 to current: approved to discuss what is in the public domain
Inotek: 2017-current
Iqvia: 2018-current
Janssen/J&J: 2015-current
KannaLife: 2019-current
Laboratory for Advanced Medicine: 2019-current
Labyrinth Holdings: 2017-current
Lilly: 2017-current
MedImmune: 2015-current
Merck: 2017-current
New Enterprise Associates: 2020-current
Ogilvy CommonHealth: 2017-current
Organovo: 2017-current
Patient Connect: 2017-current
ProdigY Biotech: 2020-current
Prometheus Laboratories: 2017-current
Refuah Solutions: 2020-current
Regulus Therapeutics: 2019-current
Salix: 2019-current
Shionogi Inc: 2017-current
Spring Bank: 2018-current
Trimaran: 2017-current

Speakers Bureau:
These speaker bureau activities focus on HBV, HCV, and liver cancer; specifically, epidemiology, diagnosis, and treatment. In addition, program presentations on vaccination for HBV and management of complications of cirrhosis.

Dr. Gish has a speaker’s contract to do promotional talks for: AbbVie, Bayer, BMS, Eisai, Gilead Sciences Inc., Intercept, Salix

Minor stock shareholder (liver space noted only):
RiboSciences, CoCrystal 

Stock Options: Eiger, Genlantis, HepQuant, AngioCrine

Other Financial Support or Material Support: None

Full details of all current and historical Research Grant Support– See my current CV Leadership Position, Other than Employment other than at Stanford University– None

Expert Testimony for Pharma (Intellectual Property) in the last 7 years– Janssen (expert witness in a litigation case), USP Pharma (expert witness in a litigation case)

Leadership Position, Other than Employment: None

Other Remuneration from Pharma: None